SCHEMBL4516365

SCHEMBL4516365

COc1cccc(Cl)c1CC1CCN(C2CCCCC2)C1=O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.54
LMNA P02545 4/20 0.42
ALDH1A1 P00352 3/20 0.41
TP53 P04637 2/20 0.40
GAA P10253 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
ABCB1 P08183 1/20 0.40
TSHR P16473 2/20 0.39
KMT2A Q03164 4/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 3/20 0.39
SIGMAR1 Q99720 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4514002 0.92 HSD11B1 (0.60) HSD11B1LMNAALDH1A1TP53GAA
SCHEMBL4513738 0.89 HSD11B1 (0.52) HSD11B1LMNAALDH1A1TP53GAA
SCHEMBL2994425 0.89 HSD11B1 (0.41) HSD11B1LMNATP53KMT2AMEN1
SCHEMBL2994420 0.89 HSD11B1 (0.41) HSD11B1LMNATP53KMT2AMEN1
SCHEMBL5541309 0.88 HSD11B1 (0.49) HSD11B1LMNAALDH1A1TP53GAA
SCHEMBL3553955 0.88 HSD11B1 (0.64) HSD11B1LMNAALDH1A1NPSR1KMT2A
SCHEMBL3000390 0.86 HSD11B1 (0.51) HSD11B1LMNAALDH1A1TP53GAA
SCHEMBL4523062 0.85 HSD11B1 (0.48) HSD11B1LMNAALDH1A1GAAKMT2A
SCHEMBL4516411 0.84 HSD11B1 (0.47) HSD11B1LMNA
SCHEMBL2998486 0.84 HSD11B1 (0.48) HSD11B1LMNAALDH1A1TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885LMNA 2846/4885ALDH1A1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.